Adocia – About the Company
Adocia is a biotechnology company focused on the development of best-in-class medicines from already approved therapeutic proteins. Founded in 2005 by the current management team, the Company successfully completed an initial public offering (IPO) in February 2012 and trades on the NYSE Euronext. Utilizing their proprietary BioChaperone platform technology, Adocia aims to provide significantly improved biologics in a low-cost, safe, and reliable manner. Currently, the Company is focused on two major therapeutic areas: wound healing and diabetes. They have successfully completed a Phase II study for the treatment of diabetic foot ulcers and are planning Phase III trials for diabetic foot ulcers and phase II trials for venous ulcers, and have also completed a Phase IIa trial for its lead fast-acting BioChaperone human insulin candidate, HinsBet. In December 2011, Adocia formed a partnership with Eli Lilly potentially worth $165 million to develop a BioChaperone Humalog formulation, which is currently in Phase I testing. Adocia is also planning to initiate Phase I trials for a proprietary combination of fast and long-acting insulins. In addition to this clinical pipeline, Adocia has established two preclinical collaboration agreements for the development of BioChaperone monoclonal antibodies.